Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who had previously received two doses of ChAdOx1 or he...

Full description

Bibliographic Details
Main Authors: Passakorn Wanchaijiraboon, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Yong Poovorawan, Nasamon Wanlapakorn, Suebpong Tanasanvimon, Virote Sriuranpong, Thiti Susiriwatananont, Nicha Zungsontiporn, Nussara Pakvisal
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Vaccines
Subjects:
ChAdOx1
CoronaVac
BNT162b2
mRNA-1273
booster COVID-19 vaccine
safety
Online Access:https://www.mdpi.com/2076-393X/11/2/356

Internet

https://www.mdpi.com/2076-393X/11/2/356

Similar Items